JP2013501033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501033A5 JP2013501033A5 JP2012523344A JP2012523344A JP2013501033A5 JP 2013501033 A5 JP2013501033 A5 JP 2013501033A5 JP 2012523344 A JP2012523344 A JP 2012523344A JP 2012523344 A JP2012523344 A JP 2012523344A JP 2013501033 A5 JP2013501033 A5 JP 2013501033A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- lipocalin
- lipocalin mutein
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23136509P | 2009-08-05 | 2009-08-05 | |
| US61/231,365 | 2009-08-05 | ||
| PCT/EP2010/061436 WO2011015634A2 (en) | 2009-08-05 | 2010-08-05 | Controlled release formulations of lipocalin muteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012176112A Division JP5774557B2 (ja) | 2009-08-05 | 2012-08-08 | リポカリン突然変異タンパク質の制御放出製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501033A JP2013501033A (ja) | 2013-01-10 |
| JP2013501033A5 true JP2013501033A5 (enExample) | 2013-09-12 |
Family
ID=43531164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523344A Pending JP2013501033A (ja) | 2009-08-05 | 2010-08-05 | リポカリン突然変異タンパク質の制御放出製剤 |
| JP2012176112A Expired - Fee Related JP5774557B2 (ja) | 2009-08-05 | 2012-08-08 | リポカリン突然変異タンパク質の制御放出製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012176112A Expired - Fee Related JP5774557B2 (ja) | 2009-08-05 | 2012-08-08 | リポカリン突然変異タンパク質の制御放出製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120201873A1 (enExample) |
| EP (2) | EP2461800A2 (enExample) |
| JP (2) | JP2013501033A (enExample) |
| KR (1) | KR20120099371A (enExample) |
| CN (2) | CN102612362A (enExample) |
| AU (2) | AU2010280688A1 (enExample) |
| BR (1) | BR112012002709A2 (enExample) |
| CA (1) | CA2770149A1 (enExample) |
| IN (1) | IN2012DN00407A (enExample) |
| RU (1) | RU2012107812A (enExample) |
| WO (1) | WO2011015634A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2791278C (en) | 2010-02-25 | 2015-11-24 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| WO2012118323A2 (ko) * | 2011-02-28 | 2012-09-07 | 고려대학교 산학협력단 | 알부민과 레티놀 결합 단백질의 융합 단백질 |
| US10064915B2 (en) | 2011-02-28 | 2018-09-04 | Korea University Research And Business Foundation | Fusion protein comprising albumin and retinol-binding protein |
| US9701732B2 (en) | 2011-02-28 | 2017-07-11 | Korea University Research And Business Foundation | Fusion protein comprising albumin and retinol-binding protein |
| BR112013027222B1 (pt) * | 2011-06-14 | 2022-07-12 | Ipsen Pharma S.A.S. | Composição de liberação sustentada que contém peptídeos como ingrediente ativo |
| WO2013068590A1 (en) * | 2011-11-11 | 2013-05-16 | Pieris Ag | Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization |
| EP2802341B1 (en) * | 2012-01-09 | 2019-03-06 | Pieris Pharmaceuticals GmbH | Methods for preventing, treating or diagnosing disorders |
| JP6184982B2 (ja) | 2012-02-02 | 2017-08-23 | エスバテック − ア ノバルティス カンパニー エルエルシー | 点眼用抗体含有徐放性製剤 |
| EP2825207B1 (en) | 2012-03-16 | 2020-08-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| AU2013232297B2 (en) | 2012-03-16 | 2016-01-14 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| US9533068B2 (en) | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
| WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| CN103394094B (zh) * | 2013-07-16 | 2015-05-13 | 天津大学 | 基于牛血清白蛋白-聚己内酯的高分子脂质体及其制备方法 |
| CN103360609B (zh) * | 2013-07-16 | 2015-08-19 | 天津大学 | 一种双亲性的蛋白质-高分子键合体及其制备方法 |
| US10927154B2 (en) | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US20160151511A1 (en) | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
| CA2974715C (en) | 2015-01-27 | 2020-05-05 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| AU2016258977C1 (en) | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| BR112018016774A2 (pt) * | 2016-02-16 | 2018-12-26 | Strongbridge Ireland Limited | veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônio |
| US12496279B2 (en) | 2019-04-11 | 2025-12-16 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| WO1997004747A1 (en) | 1995-07-27 | 1997-02-13 | Dunn James M | Drug delivery systems for macromolecular drugs |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CN1170543C (zh) | 1998-06-08 | 2004-10-13 | 弗·哈夫曼-拉罗切有限公司 | PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| BR9917517A (pt) | 1999-10-08 | 2002-07-30 | Shearwater Corp | Derivados poliméricos heterobifuncionais e processo para a preparação dos mesmos |
| AU2000202A (en) * | 2000-10-31 | 2002-05-15 | Pr Pharmaceuticals Inc | Methods and compositions for enhanced delivery of bioactive molecules |
| EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| BRPI0409322B8 (pt) | 2003-04-11 | 2021-05-25 | Antriabio Inc | método para preparar um conjugado de insulina-polímero |
| WO2005009356A2 (en) * | 2003-07-15 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Method for the preparation of controlled release formulations |
| AU2004259209A1 (en) * | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| WO2005019255A1 (en) * | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US8598317B2 (en) * | 2006-03-20 | 2013-12-03 | Technische Universitaet Muenchen | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 |
| SG173332A1 (en) * | 2006-08-01 | 2011-08-29 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| US8178483B2 (en) * | 2007-03-30 | 2012-05-15 | Colgate-Palmolive Company | Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same |
| EP2142293A2 (de) * | 2007-04-26 | 2010-01-13 | Basf Se | Enzymatisches verfahren zur herstellung von mikrokapseln |
| ES2443537T3 (es) * | 2007-07-26 | 2014-02-19 | Aqtis Ip Bv | Micropartículas que comprenden PCL y usos de las mismas |
| EP2249809A1 (en) * | 2008-01-15 | 2010-11-17 | Abbott GmbH & Co. KG | Powdered protein compositions and methods of making same |
| CN106986926A (zh) * | 2008-01-30 | 2017-07-28 | 皮里斯股份公司 | 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法 |
| US20090274623A1 (en) * | 2008-01-30 | 2009-11-05 | General Electric Company | In vivo imaging agents for met receptor tyrosine kinase |
-
2010
- 2010-08-05 AU AU2010280688A patent/AU2010280688A1/en not_active Abandoned
- 2010-08-05 US US13/388,788 patent/US20120201873A1/en not_active Abandoned
- 2010-08-05 EP EP10747840A patent/EP2461800A2/en not_active Withdrawn
- 2010-08-05 EP EP12177932.6A patent/EP2550958B1/en not_active Not-in-force
- 2010-08-05 RU RU2012107812/15A patent/RU2012107812A/ru not_active Application Discontinuation
- 2010-08-05 CA CA2770149A patent/CA2770149A1/en not_active Abandoned
- 2010-08-05 CN CN2010800348503A patent/CN102612362A/zh active Pending
- 2010-08-05 WO PCT/EP2010/061436 patent/WO2011015634A2/en not_active Ceased
- 2010-08-05 IN IN407DEN2012 patent/IN2012DN00407A/en unknown
- 2010-08-05 BR BR112012002709-3A patent/BR112012002709A2/pt not_active IP Right Cessation
- 2010-08-05 CN CN201610084958.2A patent/CN106139123A/zh active Pending
- 2010-08-05 KR KR1020127005597A patent/KR20120099371A/ko not_active Ceased
- 2010-08-05 JP JP2012523344A patent/JP2013501033A/ja active Pending
-
2012
- 2012-08-08 JP JP2012176112A patent/JP5774557B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-07 AU AU2016204715A patent/AU2016204715A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012107812A (ru) | Препараты мутеинов липокалинов с контролируемым высвобождением | |
| Park et al. | Emerging PEGylated non-biologic drugs | |
| Akash et al. | IL-1Ra and its Delivery Strategies: Inserting the Association in Perspective: Akash, Rehman and Chen | |
| Wu et al. | Optimization of protein and peptide drugs based on the mechanisms of kidney clearance | |
| CN103827177B (zh) | 用于生物活性化合物的受控释放的生物可降解的、半结晶的、相分离的、热塑性多嵌段共聚物 | |
| EP2585098B1 (en) | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders | |
| Pai et al. | Poly (ethylene glycol)-modified proteins: implications for poly (lactide-co-glycolide)-based microsphere delivery | |
| JP2014526441A5 (enExample) | ||
| IL293979B1 (en) | Controlled-release cnp agonists with increased nep stability | |
| AU2017205268A1 (en) | CNP prodrugs with large carrier moieties | |
| JP2013519697A5 (enExample) | ||
| TW201012489A (en) | Encapsulation of biologically active agents | |
| JP4966434B2 (ja) | 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化 | |
| JP2015227385A (ja) | 血液凝固タンパク質複合体 | |
| Yi et al. | Brain delivery of proteins via their fatty acid and block copolymer modifications | |
| WO2020093789A1 (zh) | 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用 | |
| CN102038938A (zh) | 利用IFN-β治疗慢性炎性脱髓鞘性多神经病 | |
| US11674959B2 (en) | Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors | |
| Bansal et al. | Nanopharmacy: Exploratory Methods for Polymeric Materials | |
| CN119390758B (zh) | 一种靶向dec-205口服疫苗及其构建方法与应用 | |
| CN114075265A (zh) | 一种多肽酪氨酸酪氨酸类似物以及包含其的缓释制剂 | |
| AU2024299322A1 (en) | Compositions and methods for delivery of therapeutic peptides | |
| WO2024233456A1 (en) | Variants of adrenomedullin (am) and adrenomedullin 2/intermedin (am2/imd) and methods of use | |
| CN121013862A (zh) | 胰高血糖素样肽-1受体激动剂变体及其方法 | |
| Hameed et al. | Controlled Release of Therapeutic Proteins |